The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

MARKET EYE-Sun Pharma gains on better outlook for key drug

Fri, 23rd Aug 2013 06:36

* Sun Pharmaceutical Industries Ltd up 1 percent aftera competitor raised its revenue guidance, citing strong sale ofa generic antibiotic also sold by Sun Pharma.* Hikma Pharmaceuticals Plc on Wednesday raised itsfull-year revenue forecast for the third time in four months,riding on strong sales of generic antibiotic doxycycline, a drugused to prevent and treat malaria and other infections. * Analysts expect generic doxycycline to contribute aroundUS$60-80 million in sales in FY14 for Sun Pharma. (abhishek.vishnoi@thomsonreuters.com /;abhishek.vishnoi.thomsonreuters.com@reuters.net)

Related Shares

More News
3 May 2024 09:14

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

26 Apr 2024 13:36

UK dividends calendar - next 7 days

25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth readi...

25 Apr 2024 10:15

Hikma Pharmaceuticals backs outlook after making strong start to 2024

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reported an encouraging start to the year supported by all three business segments.

25 Apr 2024 08:01

Hikma delivers strong Q1, holds on to guidance

(Sharecast News) - Pharmaceuticals group Hikma said it has made a "strong and encouraging start" to 2024, with all three business segments performing ...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.